DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART). The study demonstrated that AGS-004 is capable of producing a proliferative T cell response to HIV-1 antigens in patients, with full or partial HIV-specific proliferative immune responses occurring in 78% of evaluable subjects.
